Cargando…
RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/th...
Autores principales: | Honjo, Hajime, Watanabe, Tomohiro, Kamata, Ken, Minaga, Kosuke, Kudo, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079979/ https://www.ncbi.nlm.nih.gov/pubmed/33935757 http://dx.doi.org/10.3389/fphar.2021.650403 |
Ejemplares similares
-
IL-33 as a Critical Cytokine for Inflammation and Fibrosis in Inflammatory Bowel Diseases and Pancreatitis
por: Kurimoto, Masayuki, et al.
Publicado: (2021) -
Regulation of type I IFN responses by deubiquitinating enzyme A in inflammatory bowel diseases
por: Masuta, Yasuhiro, et al.
Publicado: (2023) -
Alterations of autophagic and innate immune responses by the Crohn’s disease-associated ATG16L1 mutation
por: Okai, Natsuki, et al.
Publicado: (2022) -
Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease
por: Minaga, Kosuke, et al.
Publicado: (2021) -
Case Report: New-Onset Rheumatoid Arthritis Following COVID-19 Vaccination
por: Watanabe, Tomohiro, et al.
Publicado: (2022)